KIM-1 ( P ANOVA =0.001) was also among the top 3 signals for the progression to severe albuminuria together with PCSK9 ( P ANOVA =0.001), and ASGR1 ( P ANOVA =3.510 -5 )
In summary, the therapeutic rationale for dual GLP-1/GIP receptor agonists in the treatment of obesity and Type 2 Diabetes is to harness and enhance the physiological roles of these incretins in glucose regulation and weight management, while optimizing the drug's signaling to improve efficacy, duration of action, and tolerability.The science underpinning the use of GLP-1 and GIP receptor agonists in the treatment of obesity and type 2 diabetes (T2D) is well-established, but some aspects are still subject to ongoing research and debate
The stuff you see on reality TV about weeks of pain is not typical for our patients
The biological activities of vitamin D and its receptor in relation to calcium and bone homeostasis, cancer, immune and cardiovascular systems, skin biology, and oral health
doi: 10.1126/science.1209985 34 SalamoneGLombardiGGoriSNahmodKJancicCAmaralMMet al